Text Size Normal Text Sizing Button Medium Text Sizing Button Large Text Sizing Button Text Contrast Normal Contrast Button Reverse Contrast ButtonSwitch to Spanish Language Press Room Contact Us Sitemap Sign In Register
Link to Homepage About BrightFocus
BrightFocus
Donate Now Get Involved  
Alzheimer's Disease Research Macular Degeneration Research National Glaucoma Research


Stay Informed: Medical and Research Updates
Connect With Us!
 

 

New BrightFocus-Funded Study Examines Effect of Early Drug Administration on Alzheimer's

New Experimental Drug Dampens Immune Response, Protects Brain Cells, Slows Onset and Progression of Disease in Mice

July 25, 2012

Source: The Journal of Neuroscience

Dr. Linda Van EldikFindings: A growing body of experimental data in animals and clinical observations in patients raise the possibility that uncontrolled brain inflammation could contribute to Alzheimer's disease onset and progression. Dr. Linda Van Eldik, who was funded by Alzheimer's Disease Research, led a collaborative team of researchers from the University of Kentucky and Northwestern University to test an experimental anti-inflammation drug, called MW-151, in mice carrying a human form of early-onset Alzheimer's disease. This drug, which selectively suppresses inflammation by dampening the production of pro-inflammatory proteins, when given to younger mice, seems to slow the onset and progression of disease. Advantages of MW-151 are that it can be taken by mouth and readily enters the brain—which are desirable properties not held by many other Alzheimer's drug candidates.

Significance: Dr. Van Eldik and colleagues have found that treating young mice at risk for Alzheimer's with a new oral anti-inflammatory drug candidate can protect the brain from damage and slow disease onset and progression. If more laboratory tests confirm the effectiveness of MW-151, this drug promises to be an exciting candidate for future clinical trials. The findings of this research also suggest that other anti-inflammatory treatments should be given in a more preventive fashion, before a full set of symptoms appear, to maintain brain cell connections and functions.

View all news updates for Alzheimer's disease


Disclaimer: The information provided in this section is a public service of the BrightFocus Foundation, and should not in any way substitute for the advice of a qualified healthcare professional, and is not intended to constitute medical advice. Although we take efforts to keep the medical information on our website updated, we cannot guarantee that the information on our website reflects the most up-to-date research. Please consult your physician for personalized medical advice; all medications and supplements should only be taken under medical supervision. BrightFocus Foundation does not endorse any medical product or therapy.

Some of the content in this section is adapted from other sources, which are clearly identified within each individual item of information.

Shop for a Cause YouTube Twitter Connect With Us Pinterest Google+